Eli Lilly and Co (LLY) : Schooner Investment Group. reduced its stake in Eli Lilly and Co by 33.33% during the most recent quarter end. The investment management company now holds a total of 4,000 shares of Eli Lilly and Co which is valued at $322,240 after selling 2,000 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Eli Lilly and Co makes up approximately 0.76% of Schooner Investment Group.’s portfolio.
Other Hedge Funds, Including , Saturna Capital Corp boosted its stake in LLY in the latest quarter, The investment management firm added 150 additional shares and now holds a total of 1,284,250 shares of Eli Lilly and Co which is valued at $103,459,180. Eli Lilly and Co makes up approx 3.18% of Saturna Capital Corp’s portfolio.Becker Capital Management Inc reduced its stake in LLY by selling 318 shares or 2.83% in the most recent quarter. The Hedge Fund company now holds 10,932 shares of LLY which is valued at $904,295. Eli Lilly and Co makes up approx 0.04% of Becker Capital Management Inc’s portfolio.Bank Of Hawaii reduced its stake in LLY by selling 3,183 shares or 22.97% in the most recent quarter. The Hedge Fund company now holds 10,675 shares of LLY which is valued at $883,036. Eli Lilly and Co makes up approx 0.09% of Bank Of Hawaii’s portfolio.Cape Cod Five Cents Savings Bank reduced its stake in LLY by selling 500 shares or 6.34% in the most recent quarter. The Hedge Fund company now holds 7,381 shares of LLY which is valued at $592,104. Eli Lilly and Co makes up approx 0.11% of Cape Cod Five Cents Savings Bank’s portfolio.
Eli Lilly and Co opened for trading at $80.33 and hit $80.62 on the upside on Monday, eventually ending the session at $80.26, with a gain of 0.05% or 0.04 points. The heightened volatility saw the trading volume jump to 27,80,381 shares. Company has a market cap of $88,594 M.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.